bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Other Current Assets
bluebird bio Inc
Other Current Assets Peer Comparison
Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Other Current Assets
$28.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
20%
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$2.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$511.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$414.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is bluebird bio Inc's Other Current Assets?
Other Current Assets
28.8m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Other Current Assets amounts to 28.8m USD.
What is bluebird bio Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
20%
Over the last year, the Other Current Assets growth was 38%. The average annual Other Current Assets growth rates for bluebird bio Inc have been -20% over the past three years , -1% over the past five years , and 20% over the past ten years .